Atavistik Bio

Harnessing the power of allostery to develop transformative medicines

Cambridge, United States · Founded 2021 · $225.3M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$225.3M
Last Round
$40.0M Extension RoundMar 2026
Rounds
4

About

Atavistik Bio is a clinical-stage biotechnology company developing novel allosteric small molecule therapeutics for rare hematological disorders and cancers. Its lead asset ATV-1601 is an oral allosteric AKT1-selective inhibitor targeting Hereditary Hemorrhagic Telangiectasia, which received FDA IND clearance and Fast Track designation in 2026. The company also advances a JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms.

Summary

Atavistik Bio is a Biotech company based in Cambridge, United States, founded in 2021. It has raised $225.3M in total across 4 rounds, most recently a $40.0M Extension Round round in Mar 2026. Investors include Lux Capital, Nextech Invest and The Column Group.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundMar 2026
$40.0M

Sign up to see all 4 rounds

Series A through Extension Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Atavistik Bio on Indexed.vc
<a href="https://indexed.vc/companies/atavistik-bio"><img src="https://indexed.vc/api/badge/company/atavistik-bio" alt="Atavistik Bio on Indexed.vc" width="260" height="76" /></a>